Colfax Corporation (CFX)
| Market Cap | 6.17B |
| Revenue (ttm) | 3.13B |
| Net Income (ttm) | 57.22M |
| Shares Out | 118.55M |
| EPS (ttm) | 0.41 |
| PE Ratio | 110.51 |
| Forward PE | 20.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $45.42 |
| Previous Close | $45.20 |
| Change ($) | 0.22 |
| Change (%) | 0.49% |
| Day's Open | 45.23 |
| Day's Range | 45.18 - 45.64 |
| Day's Volume | 418,363 |
| 52-Week Range | 26.45 - 50.26 |
Colfax (CFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CFX vs. FLS: Which Stock Is the Better Value Option?
Colfax (CFX) is poised to benefit from strong demand for its products, solid product portfolio, acquired assets and healthy cash flows.
The Dow Jones rose 30 points, while the S&P 500 rose 0.1%, and Nasdaq was flat. Make the most of this market with today's Top Buys from Q.ai's artificial intelligence.
Colfax's (CFX) Q1 earnings surpass estimates and improve year over year on sales and margin improvement. For 2021, it raises bottom-line projections.
Colfax (CFX) delivered earnings and revenue surprises of 12.82% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Colfax (NYSE:CFX) were flat in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15.79% over the past year to $0.44, which beat the estimate o...
ANNAPOLIS JUNCTION, MD, April 29, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the first quarter of 2021.
Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DALLAS--(BUSINESS WIRE)-- #djo--DJO today announced that it has completed the acquisition of MedShape, Inc., a privately held orthopedic medical device company founded in 2005.
Colfax (CFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Annapolis Junction, MD, April 14, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financia...
AUSTIN, Texas--(BUSINESS WIRE)-- #djo--DJO today announced a strategic investment in Insight Medical Systems, a technology company dedicated to wearable surgical navigation in orthopaedics.
Colfax (CFX) to redeem $700 million worth of senior notes that are due to expire in 2024 and 2026. The move will help the company to lower its debt balance.
Annapolis Junction, MD, March 25, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it has given notice ...
Colfax (CFX) reported earnings 30 days ago. What's next for the stock?
ANNAPOLIS JUNCTION, MD, March 16, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today the pricing of an underwr...
Colfax (CFX) offers 14 million common shares to the public in an underwritten offer. The funds raised will be used for funding general corporate purposes and working capital needs.
ANNAPOLIS JUNCTION, MD, March 15, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it has commenced an ...
Colfax's (CFX) plan of dividing its fabrication technology and medical technology businesses into two separate companies will likely unlock significant values for each of its businesses.
Colfax (CFX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Annapolis Junction, Maryland, March 04, 2021 (GLOBE NEWSWIRE) -- – Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its intention to separate its fabrication te...
Annapolis Junction, Maryland, March 04, 2021 (GLOBE NEWSWIRE) -- – Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its intention to separate its fabrication te...
Annapolis Junction, MD, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it has appointed Philip Okala, Chief Operating Of...
Colfax's (CFX) Q4 earnings decrease year over year, reflecting the impacts of weak sales generation and a decline in margins. For 2021, it anticipates y/y revenue and earnings growth.
Colfax (CFX) delivered earnings and revenue surprises of 4.08% and -0.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
• Reported $0.29 EPS from continuing operations and achieved $0.51 of adjusted EPS• Recently acquired two high-growth, high-gross margin medical technology businesses • Announce...
Annapolis Junction, MD, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial...
Colfax (CFX) arm DJO closes buyout of Trilliant Surgical, which will boost its product offerings and growth prospects in the foot and ankle surgery market.
After reaching record highs last week, the major indices sold off Monday and have since failed to stage a significant rally. For now, stocks look overstretched, and inflation could be right around corner.
The industrial sector is gearing up for growth in 2021. ParkerHannifin (PH), Fortune Brands (FBHS), Reliance Steel (RS), Rexnord (RXN) and Colfax (CFX) are performing well and are set to grow.
Let's see if Colfax (CFX) stock is a good choice for value-oriented investors right now from multiple angles.
Colfax's (CFX) acquisition of LiteCure will create strong growth opportunities for DJO in the physical therapy and rehabilitation market.
Colfax's (CFX) product launches, exposure in multiple markets and gains from buyouts to prove beneficial. However, the pandemic-led challenges and lower selling days remain concerning for Q4.
Colfax's (CFX) Q3 earnings reflect the impacts of poor product demand due to the pandemic, forex woes and a fall in margin. For Q4, it predicts a sequential rise in sales and earnings.
Colfax Corporation (CFX) CEO Matt Trerotola on Q3 2020 Results - Earnings Call Transcript
Colfax (CFX) delivered earnings and revenue surprises of 2.50% and 6.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ANNAPOLIS JUNCTION, MD, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the third quarter of 2020.
Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Annapolis Junction, MD, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial...
Colfax (CFX) to benefit from growth opportunities in the Fabrication Technology and Medical Technology segments. Also, business in multiple end markets and cost-reduction actions are other tailwinds.
Colfax's (CFX) focus on innovation and product launches along with cost-saving measures might aid performances in the quarters ahead. Adversities caused by the pandemic and high debts are concerning.
It appears that investors are starting to take their chips off the table after an incredible run off the coronavirus-led market lows in March. For investors who anticipate that this wave of sell-offs wi...
Colfax (CFX) reported earnings 30 days ago. What's next for the stock?
Colfax's Rate Of Recovery Will Demonstrate The Strength Of Newly Transformed Portfolio
Colfax's (CFX) CEO Matt Trerotola on Q2 2020 Results - Earnings Call Transcript
Colfax's (CFX) Q2 results reflect the adverse impacts of the pandemic on product demand and forex woes. It predicts generating sequentially higher profits and positive cash flow in Q3.
Colfax (CFX) delivered earnings and revenue surprises of 50.00% and 2.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
About CFX
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as el... [Read more...]
| Industry Specialty Industrial Machinery | IPO Date May 8, 2008 |
| CEO Matthew Trerotola | Employees 15,400 |
| Stock Exchange NYSE | Ticker Symbol CFX |
Analyst Forecasts
According to 18 analysts, the average rating for CFX stock is "Buy." The 12-month stock price forecast is 52.36, which is an increase of 15.28% from the latest price.